Your browser doesn't support javascript.
loading
Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger, Isabel; Fotakis, Georgios; Offermann, Anne; Goveia, Jermaine; Daum, Sophia; Salcher, Stefan; Noureen, Asma; Timmer-Bosscha, Hetty; Schäfer, Georg; Walenkamp, Annemiek; Perner, Sven; Beatovic, Aleksandar; Moisse, Matthieu; Plattner, Christina; Krogsdam, Anne; Haybaeck, Johannes; Sopper, Sieghart; Thaler, Stefanie; Keller, Markus A; Klocker, Helmut; Trajanoski, Zlatko; Wolf, Dominik; Pircher, Andreas.
  • Heidegger I; Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
  • Fotakis G; Medical University Innsbruck, Institute of Bioinformatics, Biocenter, Innsbruck, Austria.
  • Offermann A; University Hospital Schleswig Holstein, Institute of Pathology, Campus Lübeck, Lübeck, Germany.
  • Goveia J; Unicle Biomedical Data Science, Leuven, Belgium.
  • Daum S; Department of Internal Medicine V, Medical University Innsbruck, Hematology and Oncology and Comprehensive Cancer Center Innsbruck (CCCI), Anichstreet 35, 6020, Innsbruck, Austria.
  • Salcher S; Department of Internal Medicine V, Medical University Innsbruck, Hematology and Oncology and Comprehensive Cancer Center Innsbruck (CCCI), Anichstreet 35, 6020, Innsbruck, Austria.
  • Noureen A; Medical University Innsbruck, Institute of Bioinformatics, Biocenter, Innsbruck, Austria.
  • Timmer-Bosscha H; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
  • Schäfer G; Department of Pathology, Medical University Innsbruck, Innsbruck, Austria.
  • Walenkamp A; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.
  • Perner S; University Hospital Schleswig Holstein, Institute of Pathology, Campus Lübeck, Lübeck, Germany.
  • Beatovic A; Unicle Biomedical Data Science, Leuven, Belgium.
  • Moisse M; Unicle Biomedical Data Science, Leuven, Belgium.
  • Plattner C; Medical University Innsbruck, Institute of Bioinformatics, Biocenter, Innsbruck, Austria.
  • Krogsdam A; Medical University Innsbruck, Institute of Bioinformatics, Biocenter, Innsbruck, Austria.
  • Haybaeck J; Department of Pathology, Medical University Innsbruck, Innsbruck, Austria.
  • Sopper S; Department of Internal Medicine V, Medical University Innsbruck, Hematology and Oncology and Comprehensive Cancer Center Innsbruck (CCCI), Anichstreet 35, 6020, Innsbruck, Austria.
  • Thaler S; Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
  • Keller MA; Medical University Innsbruck, Institute of Human Genetics, Innsbruck, Austria.
  • Klocker H; Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
  • Trajanoski Z; Medical University Innsbruck, Institute of Bioinformatics, Biocenter, Innsbruck, Austria.
  • Wolf D; Department of Internal Medicine V, Medical University Innsbruck, Hematology and Oncology and Comprehensive Cancer Center Innsbruck (CCCI), Anichstreet 35, 6020, Innsbruck, Austria.
  • Pircher A; Department of Internal Medicine V, Medical University Innsbruck, Hematology and Oncology and Comprehensive Cancer Center Innsbruck (CCCI), Anichstreet 35, 6020, Innsbruck, Austria. andreas.pircher@i-med.ac.at.
Mol Cancer ; 21(1): 132, 2022 06 18.
Article en En | MEDLINE | ID: mdl-35717322
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Próstata / Neoplasias de la Próstata Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Próstata / Neoplasias de la Próstata Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Año: 2022 Tipo del documento: Article